remdesivir

Stock transactions by members of the U.S. Congress and their spouses have been a hot topic over the last several years. A transaction disclosed late Wednesday is drawing heavy scrutiny from the public. What Happened: Sen. Rand Paul (R-KY) disclosed that his wife purchased a $1,000 to...

Shares of nano-cap biopharma NanoViricides, Inc. (NASDQ: NNVC) were trading solidly higher Tuesday following a positive data readout. What Happened: Two NanoViricides COVID-19 clinical drug candidates — NV-CoV-2 and NV-CoV-2-R — have shown "strong pan-coronavirus...

Daniel O’Day, the CEO of Gilead Sciences Inc. (NASDAQ: GILD), told CNBC on Monday that the drugmaker expects the antiviral drug to be fully effective against new strains of the coronavirus.  What Happened: O’Day appeared on CNBC’s “Squawk Box.” Gilead “has...

Eli Lilly And Co’s (NYSE: LLY) rheumatoid arthritis drug baricitinib has been issued an emergency use authorization, in combination with Gilead Sciences, Inc’s (NASDAQ: GILD) remdesivir, for the treatment of COVID-19 in adults and children who are hospitalized and require supplemental...

The United Nations World Health Organization said Thursday that Gilead Sciences Inc’s  (NASDAQ: GILD) remdesivir is not recommended for the treatment of COVID-19, the Wall Street Journal reports.  What Happened: The international agency’s panel, which advises it on...

Gilead Sciences Inc (NASDAQ: GILD) has slashed its earnings guidance for 2020, pointing to a “dynamic," "complex,” and evolving global health care environment affecting the revenue from its remdesivir drug for COVID-19. What Happened: Remdesivir, also known by its brand name...

Gilead Sciences, Inc. (NASDAQ: GILD) is the first company to receive full FDA approval for a COVID-19 treatment. The Gilead Analyst: Raymond James analyst Steven Seedhouse has a Market Perform rating on Gilead shares.  The Gilead Thesis: Veklury, generic name remdesivir, was ...

The U.S. Food and Drug Administration has approved the antiviral Veklury, commonly known as remdesivir, for the treatment of hospitalized patients with COVID-19. What Happened: Gilead Sciences' (NASDAQ: GILD) remdesivir is approved for patients that are at least 12 years of age. The...

Gilead Sciences, Inc.'s (NASDAQ: GILD) antiviral drug remdesivir has been found to have "little or no effect on mortality on hospitalized COVID-19," a global study conducted by the World Health Organization has concluded. The study is posted on a pre-print...

In the race to get COVID-19 treatment options to market, Eli Lilly is the latest to suffer a setback. What Happened: The New York Times reports Eli Lilly and Co (NYSE: LLY) paused its Phase 3 clinical trial for the ACTIV-3 antibody treatment. The pause comes as there is a...

Gilead Sciences, Inc. (NASDAQ: GILD) shares were trading higher Friday after the company announced the publication of final results from the Phase 3, NIAID-sponsored trial of Veklury in adults hospitalized with mild-to-moderate COVID-19. What Happened: The final results of the ACTT-1 study...

President Donald Trump has taken several treatments to combat the coronavirus diagnosis he received last week. Among them are an experimental antibody cocktail from Regeneron Pharmaceuticals (NASDAQ: REGN) and remdesivir, an antiviral treatment from Gilead Sciences (NASDAQ: GILD). About Remdesivir...

President Donald Trump was taken to the Walter Reed Medical Center on Friday to treat his coronavirus diagnosis. While at Walter Reed, Trump was given several treatments including an experimental antibody treatment from Regeneron Pharmaceuticals (NASDAQ: REGN) and remdesivir, an anti-viral from...

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session. On any given day, the...

Editor's note: This story has been updated to reflect a new Saturday afternoon statement from the White House on the timeline of the president's coronavirus infection and additional reports on the president's condition.  President Donald Trump is “doing very well” at...